Maksim Mamonkin, Ph.D.
Picture

Maksim Mamonkin, Ph.D.
Assistant Professor
Positions
- Assistant Professor
-
Pathology & Immunology
Center for Cell and Gene Therapy
Baylor College of Medicine
Houston, TX US
- Member
-
Dan L Duncan Comprehensive Cancer Center
Baylor College of Medicine
Houston, Texas United States
Education
- PhD from Baylor College of Medicine
- 10/2013 - Houston, Texas United States
Professional Interests
- Immunobiology of chimeric antigen receptor (CAR) T cells
- Adoptive T cell therapy of cancer and autoimmune diseases
- Clinical trials of CAR T cells in hematologic malignancies
- Synthetic biology in cell therapies
Professional Statement
The main research interest of my laboratory is studying immunobiology of T-cells engineered with chimeric antigen receptors (CARs) and creating new cell therapies for devastating diseases. We investigate molecular mechanisms regulating the activity of CAR T-cells and develop new ideas, from bench all the way to bedside. In particular, we are utilizing protein engineering and CRISPR-mediated genome editing to create therapeutic T-cells that target malignant T-cells (T-ALL, T-cell lymphoma) with minimal damage to normal lymphocytes. We are also exploring new strategies to target pathogenic T-cells in the context of immune rejection and autoimmune diseases. These approaches are currently being translated to the clinic and evaluated in ongoing and upcoming Phase I clinical trials at BCM.Websites
Selected Publications
- Mo F, Watanabe N, McKenna MK, Hicks MJ, Srinivasan M, Gomes-Silva D, Atilla E, Smith T, Ataca Atilla P, Ma R, Quach D, Heslop HE, Brenner MK, Mamonkin M. "Engineered off-the-shelf therapeutic T cells resist host immune rejection." Nat Biotechnol. 2021 Jan 1 Pubmed PMID: 32661440
- Gomes-Silva D, Srinivasan M, Sharma S, Lee CM, Wagner DL, Davis TH, Rouce RH, Bao G, Brenner MK, Mamonkin M "CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies.." Blood. 2017 Jul Pubmed PMID: 28539325
- Gomes-Silva D, Mukherjee M, Srinivasan M, Krenciute G, Dakhova O, Zheng Y, Cabral JMS, Rooney CM, Orange JS, Brenner MK, Mamonkin M "Tonic 4-1BB Costimulation in Chimeric Antigen Receptors Impedes T Cell Survival and Is Vector-Dependent." Cell Rep. 2017 Oct Pubmed PMID: 28978471
- Mamonkin M, Mukherjee M, Srinivasan M, Sharma S, Gomes-Silva D, Mo F, Krenciute G, Orange JS, Brenner MK "Reversible Transgene Expression Reduces Fratricide and Permits 4-1BB Costimulation of CAR T Cells Directed to T-Cell Malignancies." Cancer Immunol Res. 2017 Oct 27 Pubmed PMID: 29079655
- Mamonkin M, Rouce RH, Tashiro H, Brenner MK. "A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies.." Blood. 2015 Aug Pubmed PMID: 26056165
Funding
- P50 SPORE IN LYMPHOMA (2017-2022) NIH
- High Impact High Reward (2021-2023) CPRIT
- SCOR (2018-2023) Leukemia and Lymphoma Society
- Translational Research Award (2018-2021) Leukemia and Lymphoma Society
- Dream Team in T-cell Lymphoma ( Stand Up to Cancer (2019-2023)
Log In to edit your profile